格隆汇12月18日丨戴维医疗(300314.SZ)公布，全资子公司宁波维尔凯迪医疗器械有限公司（简称"维尔 凯迪"）于近日取得由浙江省药品监督管理局颁发的1项《医疗器械注册证》，维尔凯迪产品一次性使用 腔镜切割吻合器及组件完成了延续注册。 ...

本次延续注册的完成，使得维尔凯迪可以继续生产和销售一次性使 用腔镜切割吻合器及组件，对公司未来经营将产生积极影响。上述产品 的实际销售情况取决于未来市场推广效果，公司目前尚无法预测其对公 司未来业绩的影响，敬请投资者注意投资风险。 证券代码：300314 证券简称：戴维医疗 公告编号：2025-089 宁波戴维医疗器械股份有限公司 关于全资子公司部分医疗器械产品完成延续注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司 宁波维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日取得 由浙江省药品监督管理局颁发的1项《医疗器械注册证》，维尔凯迪产品 一次性使用腔镜切割吻合器及组件完成了延续注册，具体如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期至 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 1 | 一次性使用腔 | 浙械注准 | 2031.7.19 | Ⅱ类 | 产品用于腔镜下消化 | | | 镜切割吻合器 | ...

Group 1 - The core point of the article is that David Medical (300314.SZ) has recently obtained a medical device registration certificate from the Zhejiang Provincial Drug Administration for its multi-parameter monitor, completing the renewal of its registration [1] Group 2 - The company’s product, the multi-parameter monitor, is crucial for patient monitoring in medical settings, indicating its importance in the healthcare industry [1] - The renewal of the registration certificate suggests that the company is maintaining compliance with regulatory standards, which is essential for its operational continuity [1] - This development may enhance the company's market position and potentially lead to increased sales in the medical device sector [1]

Group 1 - The core point of the article is that David Medical (300314.SZ) has recently obtained a medical device registration certificate from the Zhejiang Provincial Drug Administration for its multi-parameter monitor, completing the renewal of its registration [1] Group 2 - The company’s product, the multi-parameter monitor, is crucial for patient monitoring in medical settings, indicating its importance in the healthcare industry [1] - The renewal of the registration suggests that the company is maintaining compliance with regulatory standards, which is essential for its operational continuity [1] - This development may enhance the company's market position and potentially lead to increased sales in the medical device sector [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-088 宁波戴维医疗器械股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日取得由 浙江省药品监督管理局颁发的1项《医疗器械注册证》，公司产品多参数 监护仪完成了延续注册，具体如下： | 序号 | 产品名称 | 注册证编号 | 注册证有效期至 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | | 1 | 多参数监护仪 | 浙械注准 | 2031.6.2 | Ⅱ类 | 用于医疗机构对患者进行心 | | | | 20212070235 | | | 电（ECG）、心率（HR）、呼 | | | | | | | 吸 （ Resp ） 、 血 氧 饱 和 度 | | | | | | | （SpO2）、脉率（PR）、无创 | | | | | | | 血压（NIBP）、体温（Temp）、 | | | | | | | 二氧化碳（CO2）生理参数的 | | | | | | | 监测。 | 本次延续 ...

证券日报网讯12月12日，戴维医疗（300314）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东总户数约为19300户。 ...

Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

Core Viewpoint - David Medical (300314.SZ) has received the Medical Device Registration Certificate from the Zhejiang Provincial Drug Administration for its new product, the electric surgical table, which is essential in surgical treatment [1] Group 1: Product Features - The electric surgical table is designed to support patients, adjust surgical positions, and fully expose the surgical field, allowing medical staff to perform various surgeries comfortably and efficiently [1] - The core value of the electric surgical table lies in its safety, comfort, usability, and durability [1] - The table utilizes an electric hydraulic control system, enabling flexible control of various movements through a micro-button switch controller to meet diverse surgical positioning requirements [1] Group 2: Functional Capabilities - The electric surgical table can maintain high load-bearing capacity in any position, accommodating the variability of surgeries and different patient positions [1] - Its modular design allows for adaptability to a wide range of surgical procedures, and the simple button connection joints enhance operational ease [1]

Core Viewpoint - David Medical has received a medical device registration certificate from the Zhejiang Provincial Drug Administration for its electric surgical tables, which will enhance the company's product line and core competitiveness, positively impacting future business results [1] Group 1: Product Registration - The product name is electric surgical table, with model specifications including DT-100/DT-100A/DT-100B/DT-100C/DT-100D [1] - The registration classification is Class II, and the certificate is valid until December 7, 2030 [1] - The product is applicable for various surgical procedures, including general surgery, neurosurgery, thoracic and abdominal surgery, orthopedics, urology, colorectal surgery, plastic surgery, gynecology, hepatobiliary surgery, and general surgery [1] Group 2: Business Impact - The acquisition of the medical device registration certificate is expected to enrich the company's product line and enhance its core competitiveness [1] - The future impact of these products on the company's revenue remains uncertain [1]

Core Viewpoint - The company announced that its electric surgical table has received the Medical Device Registration Certificate from the Zhejiang Provincial Drug Administration, which is expected to enhance its product line and core competitiveness, positively impacting future operational results [1] Product Details - The electric surgical table is designed for various medical procedures, including general surgery, neurosurgery, thoracic and abdominal surgery, orthopedics, urology, colorectal surgery, plastic surgery, gynecology, hepatobiliary surgery, and general surgery [1] Market Impact - The acquisition of the medical device registration certificate is anticipated to enrich the company's product offerings and strengthen its competitive position in the market [1] - The company is currently unable to predict the impact of these products on future revenue [1]